Company Overview and News
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C8F)D [email protected]&)@8)H%(ADKP&0[B&29 R*9SX%E2\!D 5BD&\S.!K/#P>PJ,+D72#(* M>X/964#R_P47!B:@^;=!(D!3:4+^9V"<^[email protected] "R(0TM#0IE;F1S=')E86T- M96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HQ,#@@,"!O M8FH-/#PO0R Q,#0O1FEL=&5R+T9L871E1&5C
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
EQT CRK EOG
Diamondback Energy (FANG), an oil and gas company operating in the Permian Basin in Texas, is poised for strong, above average stock gains as the company ramps up production. FANG increased proved reserves 63% in 2017 to 335.4 MMboe. The company achieved a 52% compound annual growth rate for total reserves since 2013.
The U.S. Energy Department's weekly inventory release showed a larger-than-expected increase in natural gas supplies. Despite the headline miss, the report pointed to a tightening market dynamic and boosted the fuel’s price, which added around 1.5% for the week.
CKRGZ WPXP CHKVP CRK COG CHKDH CHKVZ WPX AR CHKDG CHKWZ CHKDJ CHKDP EQT CHK CHK.WI CHK.PRD
Soros' 13F portfolio value increased from $4.37B to $6.16B this quarter. The number of positions increased from 196 to 219.
CRC VR ALLT TEVA AEO AET KWN.CL UTX CZR GPS CPV LIVN FG TIVO LH TMO CCV NXPI WFC.PRL NFLX CCZ WFC.PRJ GLIBA BAX VR.PRA EXR VR.PRB BAC WFC.PRT KW WFC.PRR VRX WFC.PRQ WFC.PRP WFC.PRO WFC.PRN SEDG CI CCI WFC.PRY WFC.PRX WFC.PRW WFC.PRV CBS LBRDB CACQ LBRDK JPM CCV.CL LBRDA PLAY LRCX DISCB XON DISCA TWX DISCK VICI EQT AMZN GM.WS.A AABA GM.WS.B GM.WS.C CMCSK DISC OSTK BAC QQQ TTWO LGF VRX CBS.WD TWC XLGLF GM.WSB WFCNP SIGM HAL CHDN XL KWN GM DIS WFC WFC.WS C CBS.A CMCSA ZAYO COL TGT T LGF.A LGF.B URBN SBAC
The U.S. Energy Department's weekly inventory release showed a smaller-than-expected increase in natural gas supplies. The bullish report boosted the fuel’s price, which added around 3.5% for the week.
EQT WPXP CHK CRK COG WPX AR
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to EQT / EQT Corp. on message board site Silicon Investor.
|EQTL Equitech where technlogy development meets Wallst.||Paragon Real Estate Eqty Invst|
|Equitex (EQTX)||UNDISCOVERED INTERNET BANK EQUITEX(EQTX)WAKING UP|
as of ET